ACR Convergence 2022 Archives - ACR Meeting Abstracts

Abstract Number: 1583

Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Abstract Number: 0131

Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study
Abstract Number: 1100

Racial Differences in Clinical Trial Perceptions Among a Large, Predominantly Black Cohort of Patients with Systemic Lupus Erythematosus in the Southeastern United States
Abstract Number: 0116

Racial Differences in Medication Beliefs and Barriers to Taking Medications Among Patients with SLE
Abstract Number: 1861

Racial Disparities in Diagnosis and Treatment of Patients with Dermatomyositis of Different Skin Tones
Abstract Number: 0728

Racial Disparities in Pain: Severity, Interference with Function, and Response to Guided Imagery
Abstract Number: 0843

Racial Disparities in Patient Satisfaction Following Total Joint Arthroplasty: A Contemporary Trends Analysis from 2013-2021
Abstract Number: 0089

Racial Disparities in Rheumatology Clinical Trials
Abstract Number: 1935

Racial Disparities Influence Healthcare Utilization in Pediatric Rheumatology Clinic
Abstract Number: 0299

Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib
Abstract Number: 1898

Radiographic Osteoarthritis Progression Can Be Predicted via Pyrosequencing Analysis of Baseline Peripheral Blood
Abstract Number: 1804

Raman Spectroscopy Integrated with Polarized Light Microscopy for Diagnosis of Crystallopathies
Abstract Number: 2237

Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods
Abstract Number: 0974

Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
Abstract Number: 1552

Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis
Abstract Number: 1924

Reading the Waves: Identifying Distinct Phenotypes of Multisystem Inflammatory Syndrome in Children During the 2020-2021 COVID-19 Pandemic
Abstract Number: 0243

Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
Abstract Number: 0418

Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
Abstract Number: 0076

Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database
Abstract Number: 0289

Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
Abstract Number: 0740

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
Abstract Number: 1374

Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
Abstract Number: 0347

Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Abstract Number: 0201

Real-World Evidence from Social Media Provides Insights into Patient Mental Health Outcomes in the Management of Gout
Abstract Number: 2138

Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
Abstract Number: 0714

Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Abstract Number: 1838

Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States
Abstract Number: 0075

Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
Abstract Number: 0074

Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US
Abstract Number: 0274

Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset
Abstract Number: 1387

Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe
Abstract Number: 0264

Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
Abstract Number: 0897

Reasons for Multiple Biologic DMARD Switching and Characteristics of “Extreme Treatment Nonresponders” in Rheumatoid Arthritis
Abstract Number: 0427

Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study
Abstract Number: 0525

Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial
Abstract Number: 2220

Recurrence of Herpes Zoster Reactivation After Events of Herpes Zoster in Patients Receiving JAK Inhibitors in South Korea: A Nationwide Population-based Study
Abstract Number: 2268

Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 0020

Redoxosomes Mediate a Feed-forward Loop of Cartilage Matrix Destruction Through α5β1 Integrin Signaling in Response to a Fibronectin Matrikine
Abstract Number: 0701

Reduced Humoral but Maintained Cellular Immune Response to a 3rd COVID-19 Vaccination in Patients with Immune-Mediated Inflammatory Diseases as Compared to Healthy Controls over a 3-months Observational Period
Abstract Number: 0637

Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals
Abstract Number: 1236

Reduced Inflammation Following 4-weeks TNF-α Inhibitor Treatment Restore Aberrant Cerebral Pain Processing in Rheumatoid Arthritis Patients: A Randomized Double-Blind Placebo-Controlled fMRI Study
Abstract Number: 2215

Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis
Abstract Number: 1807

Reduction in Monosodium Urate Crystal Deposit Volume During the MIRROR RCT Trial in Patients Treated with Pegloticase Plus Methotrexate Co-therapy: A Serial Dual-Energy Computed Tomography (DECT) Analysis
Abstract Number: 2251

Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Abstract Number: 0307

Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores
Abstract Number: 0768

Reevaluating Clinical Outcomes of Patients on Combination Biologics
Abstract Number: 1567

Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol
Abstract Number: 0618

Regulation of IgA Secretion Through PAD2-mediated Citrullination of MZB1
Abstract Number: 0867

Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration
Abstract Number: 0989

Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
Abstract Number: 0841

Relation of PainDETECT to Unpredictable Pain in People with or at Risk of Knee Osteoarthritis
Abstract Number: 1873

Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively
Abstract Number: 1401

Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
Abstract Number: 0787

Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
Abstract Number: 1355

Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials
Abstract Number: 2258

Relative Frequencies of the Spectrum of MRI Lesions in the Sacroiliac Joints of Healthy Individuals and Patients with Non-Specific Back Pain: What Is the Impact of Increasing Age?
Abstract Number: 1232

Reliability and Validity of Single Axial Slice vs. Multiple Slice Quantitative Measurement of the Volume of Effusion-Synovitis on 3T Knee MRI in Knees with Osteoarthritis
Abstract Number: 0811

Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction
Abstract Number: 2200

Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare
Abstract Number: 0853

Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?
Abstract Number: 1301

Reliable Transition Policy Distribution and Transition Readiness Assessment Questionnaire Completion Using a Digital Intervention in a Pediatric Rheumatology Clinic
Abstract Number: 1113

Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
Abstract Number: 2086

Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: PP07

Remissions and Vigilance
Abstract Number: 0758

Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
Abstract Number: 0731

Remote Monitoring of Chronic Inflammatory Musculoskeletal Diseases– Results of the Digireuma Feasibility Study
Abstract Number: 1069

Renal Involvement Other Than Renal Crisis in Systemic Sclerosis: A Retrospective Monocentric Cohort Study
Abstract Number: 0514

Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen
Abstract Number: 1543

Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR
Abstract Number: 1314

Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
Abstract Number: 1026

Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis
Abstract Number: 0851

Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
Abstract Number: 2069

Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
Abstract Number: 0589

Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation
Abstract Number: 0103

Retention in Rheumatology Care and Receipt of Lupus-Specific Serologic Testing Among Young Adults with Systemic Lupus Erythematosus: A Medicare Cohort Study
Abstract Number: 0920

Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
Abstract Number: 0133

Retention Rate of Targeted Therapies in Erdheim-Chester Disease
Abstract Number: 1434

Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis
Abstract Number: 0927

Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
Abstract Number: 0061

Rheumatic Diagnostic Code Trajectories for Patients with RA and SLE in a U.S. Rheumatology Registry
Abstract Number: 0805

Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
Abstract Number: 0756

Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
Abstract Number: 1668

Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma
Abstract Number: 0077

Rheumatoid Arthritis – Are We Getting to Target?
Abstract Number: 0891

Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
Abstract Number: 0247

Rheumatoid Arthritis as a Modifier of the Cognition-Daily Function Association
Abstract Number: 0258

Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents
Abstract Number: 0910

Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
Abstract Number: 2007

Rheumatoid Arthritis Associated Lymphoproliferative Disorders: Current Features and It’s Changing Pattern Due to the Influence of Anti-rheumatic Drugs
Abstract Number: 0121

Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Treatment Guidelines
Abstract Number: 0065

Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
Abstract Number: 2246

Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes
Abstract Number: 0045

Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACPAs) Ameliorate Joint Inflammation in Early Collagen-antibody Induced Arthritis (CAIA)
Abstract Number: 0304

Rheumatoid Arthritis Patients Who Switched Treatment from Adalimumab to Upadacitinib Demonstrate a Robust Reduction of Inflammation-related Biomarkers: Proteomics Analysis from the SELECT-COMPARE Phase 3 Study
Abstract Number: 0623

Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
Abstract Number: 0737

Rheumatologic Rashes in Different Skin Types and Confidence in Diagnosis Among Internal Medicine Residents in a New York City Hospital
Abstract Number: 1255

Rheumatologists Overcall Sacroiliitis on X-ray and MRI in Axial Spondyloarthritis Patients: Data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT (Be-GIANT)
Abstract Number: 0239

Rheumatology Fellowship Programs – What Are Our Missions and What Are We Missing? A Mixed Methods Analysis of Publically-Available Mission Statements from the 126 Adult Rheumatology Fellowships in the United States
Abstract Number: 2173

Rheumatology Telemedicine Consults: Impact of Demographic Variability on Patient Perception in Systemic Sclerosis versus Rheumatoid Arthritis Pts
Abstract Number: 0232

RheumMadness: Early Learner Experience and Impact
Abstract Number: 1981

Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
Abstract Number: 0308

Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
Abstract Number: 0710

Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
Abstract Number: 1469

Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1524

Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
Abstract Number: 1207

Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
Abstract Number: 1331

Risk Factors for Osteoporotic Fracture in Women with Established Long-Term Rheumatoid Arthritis
Abstract Number: 2196

Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System
Abstract Number: 0494

Risk for Visual Loss in Patients with Giant Cell Arteritis
Abstract Number: 0898

Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication
Abstract Number: 2075

Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids
Abstract Number: L06

Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
Abstract Number: 1396

Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Abstract Number: 0302

Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
Abstract Number: 0723

Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
Abstract Number: 1033

Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort
Abstract Number: 1648

Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Abstract Number: 1049

Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Abstract Number: 0720

Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study
Abstract Number: 0268

Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry
Abstract Number: 1520

Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre
Abstract Number: 0527

Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials
Abstract Number: 0147

Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational Study
Abstract Number: 0781

Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Abstract Number: 1084

Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
Abstract Number: 0003

Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
Abstract Number: 0931

Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial
Abstract Number: 0762

Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Abstract Number: 2096

Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 1709

Role of Corneal Langerhans Dendritic Cells in Lupus Keratitis
Abstract Number: 0482

Role of miR-146a and miR-146b in Giant Cell Arteritis
Abstract Number: 1442

Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Abstract Number: 0012

Role of Type L IFN Signaling on B Cell Pathogenicity in Early Sjögren’s Disease in Mouse Model
Abstract Number: L11

Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial